VSVincent T. H. B. M. Smit

Vincent T. H. B. M. Smit

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Vincent T. H. B. M. Smit has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Deep Learning-Based Screening for POLE mutations on Histopathology Slides in Endometrial Cancer

    by Nikki van Den Berg, Lydia Schoenpflug, Nanda Horeweg, Sarah Volinsky-Fremond, Jurriaan Barkey-Wolf, Sonali Andani, Maxime Lafarge, Gitte Ørtoft, Jan J. Jobsen, Rubina Razack, et al.

    POLE sequencing for somatic mutations ( POLE mut) guides adjuvant therapy in endometrial cancer (EC), but cost and infrastructural considerations lead to limited uptake. Omission of POLE testing leads to unnecessary exposure to radiotherapy and/or chemotherapy. We developed POLARIX, a multiple instance deep learning model with attention pooling, which predicts POLE mutation status from routine hematoxylin and eosin whole-slide images (WSIs). Trained on 2,238 cases from eleven EC cohorts, POLARIX showed clinical-grade discrimination across three external cohorts (Pooled: AUC=0.95, 95% CI: 0.91–0.98; n =68/481 POLE mut/ POLE wt). Attention maps highlight POLE morphologies. Clinical applicability is demonstrated using predefined thresholds based on three resource scenarios. The most sensitive threshold (“Low”) yields a test reduction of 77% (73%-81%) (sensitivity: 93% (85%-99%), specificity: 89% (87%-92%)). POLARIX is an interpretable and cost-efficient approach to reduce POLE testing in women with endometrial cancer, broadening access to precision oncology.


  • Open Access

    Absence of lipopolysaccharide (LPS) expression in breast cancer cells

    by Noel F. C. C. de Miranda, Vincent T. H. B. M. Smit, Manon van der Ploeg, Jelle Wesseling, Jacques Neefjes

    The relationship between bacterial activity and tumorigenesis has gained attention in recent years, complementing the well-established association between viruses and cancer. A recent study employed immunodetection of lipopolysaccharide (LPS) to demonstrate the presence of intracellular bacteria within cancer cells across various cancer types, including breast cancer. The authors proposed that these bacteria might play a role in tumor development. We sought to replicate these findings using the same experimental methods on an independent cohort of breast cancer cases. Our analysis of 129 samples revealed no evidence of LPS expression within cancer cells. Instead, LPS immunoreactivity was observed in ducts or immune cells, specifically macrophages, as expected. These discrepancies in LPS immunodetection warrant caution in interpreting the original findings, and further research is needed to clarify the potential role of intracellular bacteria in cancer development.


  • Open Access

    HECTOR: multimodal deep learning predicts recurrence risk in endometrial cancer

    by Sarah Fremond-Volinsky, Nanda Horeweg, Sonali Andani, Jurriaan Barkey Wolf, Maxime W Lafarge, Cor de Kroon, Gitte Ørtoft, Estrid Høgdall, Jouke Dijkstra, Jan J Jobsen, et al.

    Predicting distant recurrence of endometrial cancer (EC) is crucial for personalized adjuvant treatment. The current gold standard of combined pathological and molecular profiling is costly, hampering implementation. We developed HECTOR ( H istopathology-based E ndometrial C ancer T ailored O utcome R isk), a multimodal deep learning prognostic model using hematoxylin-and-eosin-stained whole-slide-images and tumor stage as input, on 1,912 patients from seven EC cohorts including the PORTEC-1/-2/-3 randomized trials. HECTOR demonstrated C-indices in internal ( n = 353) and external ( n = 151) test sets of 0.788 and 0.816 respectively, outperforming the current gold-standard, and identified patients with markedly different outcomes (10-year distant recurrence-free probabilities of 97.0%, 77.7% and 58.1% for HECTOR low, intermediate and high risk groups). HECTOR also predicted adjuvant chemotherapy benefit better than current methods. Morphological and genomic feature extraction identified correlates of HECTOR risk groups, some with therapeutic potential. HECTOR improves on the current gold-standard and may help delivery of personalized treatment in EC.

  • Open Access

    Absence of Lipopolysccharide (LPS) expression in Breast Cancer Cells

    by Noel Fcc de Miranda, Vincent Thbm Smit, Manon van der Ploeg, Jelle Wesseling, Jacques Neefjes

    The association between bacterial activity and tumorigenesis has gained attention in recent years, alongside the well-established link between viruses and cancer. A recent study proposed the presence of intracellular bacteria in cancer cells, particularly in melanomas and breast cancers, with detectable bacterial DNA. The authors suggested that these bacteria contribute to the tumors’ development. We sought to replicate these findings using the same experimental methods on different tissue microarrays. Our investigation included 129 breast cancer samples, but we found no evidence of LPS expression within cancer cells. Instead, LPS immunoreactivity was observed in ducts or immune cells, specifically macrophages. The discrepancies in LPS staining warrant caution in interpreting the reported observations, and further research is needed to elucidate the potential role of intracellular bacteria in cancer development.


  • OC-0601 Early toxicity and quality of life after molecular-based adjuvant treatment in the PORTEC-4a trial

    by A. van Den Heerik, C. Post, L. Lutgens, D. Haverkort, S. Kommoss, F. Koppe, M. Nowee, H. Westerveld, M. de Jong, D. Cibula, et al.

  • Open Access

    QPOLE: A Quick, Simple, and Cheap Alternative for POLE Sequencing in Endometrial Cancer by Multiplex Genotyping Quantitative Polymerase Chain Reaction

    by Anne Sophie V.M. Van Den Heerik, Natalja T. Ter Haar, Lisa Vermij, Jan J. Jobsen, Mariel Brinkhuis, Suzan M. Roothaan, Alicia Leon-Castillo, Gitte Ortoft, Estrid Hogdall, Claus Hogdall, et al.

    PURPOSE: Detection of 11 pathogenic variants in the POLE gene in endometrial cancer (EC) is critically important to identify women with a good prognosis and reduce overtreatment. Currently, POLE status is determined by DNA sequencing, which can be expensive, relatively time-consuming, and unavailable in hospitals without specialized equipment and personnel. This may hamper the implementation of POLE-testing in clinical practice. To overcome this, we developed and validated a rapid, low-cost POLE hotspot test by a quantitative polymerase chain reaction (qPCR) assay, QPOLE. MATERIALS AND METHODS: Primer and fluorescence-labeled 5′-nuclease probe sequences of the 11 established pathogenic POLE mutations were designed. Three assays, QPOLE-frequent for the most common mutations and QPOLE-rare-1 and QPOLE-rare-2 for the rare variants, were developed and optimized using DNA extracted from formalin-fixed paraffin-embedded tumor tissues. The simplicity of the design enables POLE status assessment within 4-6 hours after DNA isolation. An interlaboratory external validation study was performed to determine the practical feasibility of this assay. RESULTS: Cutoffs for POLE wild-type, POLE-mutant, equivocal, and failed results were predefined on the basis of a subset of POLE mutants and POLE wild-types for the internal and external validation. For equivocal cases, additional DNA sequencing is recommended. Performance in 282 EC cases, of which 99 were POLE-mutated, demonstrated an overall accuracy of 98.6% (95% CI, 97.2 to 99.9), a sensitivity of 95.2% (95% CI, 90.7 to 99.8), and a specificity of 100%. After DNA sequencing of 8.8% equivocal cases, the final sensitivity and specificity were 96.0% (95% CI, 92.1 to 99.8) and 100%. External validation confirmed feasibility and accuracy. CONCLUSION: QPOLE is a qPCR assay that is a quick, simple, and reliable alternative for DNA sequencing. QPOLE detects all pathogenic variants in the exonuclease domain of the POLE gene. QPOLE will make low-cost POLE-testing available for all women with EC around the globe.


  • Open Access

    Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry

    by Lisa Vermij, Jan J. Jobsen, Alicia León-Castillo, Mariel Brinkhuis, Suzan Roothaan, Melanie E. Powell, Stephanie M. de Boer, Pearly Khaw, Linda R. Mileshkin, Anthony Fyles, et al.

    Background: Risk-assessment of endometrial cancer (EC) is based on clinicopathological factors and molecular subgroup. It is unclear whether adding hormone receptor expression, L1CAM expression or CTNNB1 status yields prognostic refinement. Methods: Paraffin-embedded tumour samples of women with high-risk EC (HR-EC) from the PORTEC-3 trial (n=424), and a Dutch prospective clinical cohort called MST (n=256), were used. All cases were molecularly classified. Expression of L1CAM, ER and PR were analysed by whole-slide immunohistochemistry and CTNNB1 mutations were assessed with a next-generation sequencing. Kaplan-Meier method, log-rank tests and Cox’s proportional hazard models were used for survival analysis. Results: In total, 649 HR-EC were included. No independent prognostic value of ER, PR, L1CAM and CTNNB1 was found, while age, stage, and adjuvant chemotherapy had an independent impact on risk of recurrence. Subgroup-analysis showed that only in NSMP HR-EC, ER-positivity was independently associated with a reduced risk of recurrence (HR 0.33, 95%CI 0.15-0.75). Conclusions: ER-positivity is a strong favourable prognostic factor in NSMP HR-EC and identifies a homogeneous subgroup of NSMP tumours. ER-positive NSMP EC may be regarded as a novel fifth molecular subgroup. Assessment of ER status in high-risk NSMP EC is feasible in clinical practice and could improve risk stratification and treatment.

  • Exploring Morphologic and Molecular Aspects of Endometrial Cancer Under Progesterone Treatment in the Context of Fertility Preservation

    by Mignon D.J.M. van Gent, Alina R. Nicolae-Cristea, Cor D. de Kroon, Elisabeth M. Osse, Marjolein J. Kagie, J. Baptist M.Z. Trimbos, Hans Marten Hazelbag, Vincent T.H.B.M. Smit, Tjalling Bosse


  • Searching for metastases in ovarian tissue before autotransplantation: a tailor-made approach

    by Ellen J. Hoekman, Vincent T.H.B.M. Smit, Timothy P. Fleming, Leonie A. Louwe, Gert Jan Fleuren, Carina G.J.M. Hilders


  • Vaginal Brachytherapy vs. External Beam Radiotherapy for High-intermediate Risk Endometrial Cancer: Results of the Randomized PORTEC-2 Trial after Central Pathology Review

    by R.A. Nout, V.T.H.B. Smit, H. Putter, I.M. Jürgenliemk-Schulz, J.J. Jobsen, L.C.H.W. Lutgens, E.M. van der Steen-Banasik, J.M. Mens, A. Slot, C.L. Creutzberg